Clinical Trial of MGTA-456 Looks Promising for Inherited Metabolic Disorders
According to an article in BioPortfolio, Magenta Therapeutics, a biotechnology company based in Cambridge, Mass., recently announced updates to its Phase II trial of MGTA-456 for the treatment of…